Shares of Theratechnologies Inc. (TSE:TH - Get Free Report) traded up 32.4% on Thursday . The stock traded as high as C$4.33 and last traded at C$4.25. 578,691 shares changed hands during trading, an increase of 572% from the average session volume of 86,081 shares. The stock had previously closed at C$3.21.
Analyst Upgrades and Downgrades
Separately, Jones Trading upgraded Theratechnologies from a "hold" rating to a "strong-buy" rating in a research note on Friday, April 11th.
Get Our Latest Research Report on TH
Theratechnologies Stock Performance
The firm's fifty day simple moving average is C$3.59 and its 200 day simple moving average is C$2.89. The company has a debt-to-equity ratio of -293.92, a current ratio of 1.08 and a quick ratio of 0.64. The company has a market capitalization of C$134.96 million, a price-to-earnings ratio of -47.88, a PEG ratio of -8.50 and a beta of 1.73.
Theratechnologies Company Profile
(
Get Free Report)
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.
Featured Stories
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
